The statements within this website are for infomational purposes only: Disclaimer

Nobel Biocare AG

Company Information
Address Industriestrasse 9
6010 Kriens
Country Switzerland
Phone +41 (0) 41 340 30 40
Internet www.nobelbiocare.com
Business Sector Healthcare/Medical Products
Brief Overview Nobel Biocare develops, produces, and markets dental implants and IT-based industrialised dental prosthetics. The company operates two business units: Dental implant, which makes permanent replacements for lost teeth, and Procera®, a unique, fully digitized custom-manufacturing and business process of prosthetic components.
 
People
Chief Executive Officer Heliane Canepa
Chief Financial Officer Harrieth Sundaeus
Chairman of the Board Ernst Thomke
Auditors KPMG Fides
No. of Employees 1328
 
Going Public
Exchange Swiss Exchange
IPO Date June 24, 2002
Share Identification Number 1403004
Symbol NOBE
Subscription Period 01,01,2000 to 01,01,2001
Lead Underwriter UBS Warburg
Total No. of Shares in Issue after Going Public 25,347,512
No. of Offered Shares 25,347,512
Total No. of Issued Share 100%
First Day Close CHF 106
 
Numbers (in 1000 SEK)
Last Fiscal Year End Date Prior to Going Public December 31, 2001
Change Compared to Prior Year
Turnover 2001
2,663,200 26.2%
Turnover 2000
2,109,500
Change Compared to Prior Year
Operating Profit, EBIT 2001
363,700 25.6%
Operating Profit, EBIT 2000
289,600
Change Compared to Prior Year
Profit Before Tax 2001
339,000 36.8%
Profit Before Tax 2000
247,800
Change Compared to Prior Year
Company Profit 2001
189,000 40.9%
Company Profit2000
134,100
 
Company Profit 2001 reflects 7.1 % of Turnover
Company Profit 2000 reflects 6.4 % of Turnover
   
Equity on Last Balance Date 1,934,594
Total Assets 3,046,042
Ratio of Equity to Total Capital on Balance Date 63.5 %
Last Return on Equity (ROE) 9.8 %
 
Notes
The Company's stock is already traded at Stockholmbörsen since 1994. After an upcoming reorganization of the Company, the parent company of the holding will be in Switzerland. Also, the primary listing of the stock will take place at SWX Swiss Exchange.

Start